



## Virica Biotech welcomes Dr. James Taylor to our Board of Directors

**Ottawa, Canada – September 10th, 2025** –We're excited to announce that Dr. James Taylor, co-founder and former CEO of Precision NanoSystems (PNI), has joined Virica Biotech's Board.

During his tenure at PNI, James transformed the Vancouver start-up into a global leader in lipid-nanoparticle and mRNA-based genetic-medicine platforms, ultimately guiding the company through its 2021 acquisition by Danaher and successful integration into Cytiva's Life Sciences portfolio.

A trained engineer (B.A.Sc., Engineering Physics, UBC) and geneticist (Ph.D., UBC & Institute for Systems Biology), James brings deep experience in microfluidics, nanotechnology, and scaling technologies for the creation and manufacturing of advanced therapeutics. He was also a prior director with Life Sciences BC, giving him board-level insight across the Canadian biotech ecosystem.



*Dr. James Taylor,  
Ph.D.*

*"James' track record of translating cutting-edge science into commercially viable platforms aligns perfectly with Virica's mission to accelerate viral-vector manufacturing. His strategic vision and operator's mindset will be invaluable as we expand our VSE™ technology globally."* — **Jean-Simon Diallo, Ph.D., CEO, Virica Biotech**

*"Virica's science addresses a critical bottleneck in cell and gene-therapy and viral vaccine production. I'm thrilled to help the team scale their impact worldwide."* — **James Taylor, Ph.D.**

### About Virica Biotech

Virica develops cell enhancers that improve the yield and quality of viral vectors used for cell & gene therapies and vaccines, allowing developers to deploy their products at scale economically. Virica's Viral Sensitizer (VSE™) enhancers reduce production inefficiencies caused by cellular defenses in manufacturing cells. Purpose-formulated VSE combinations substantially increase manufacturing yields & reduce the cost of goods for a range of products. Beyond supplying VSEs as off-the-shelf reagents, Virica operates as a fast-turnaround service partner. Our proprietary High-Throughput Virology (HTV™) platform, Design-of-Experiments (DoE) process optimization, and analytical testing workflows enable developers to rapidly pinpoint the optimal transfection or transduction conditions, allowing programs to scale sooner and at a lower cost. [viricabiotech.com](http://viricabiotech.com)